Compare CRAI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRAI | CRVS |
|---|---|---|
| Founded | 1965 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1998 | 2016 |
| Metric | CRAI | CRVS |
|---|---|---|
| Price | $171.55 | $14.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $245.00 | $30.17 |
| AVG Volume (30 Days) | 109.8K | ★ 757.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | 20.77 | ★ 48.04 |
| EPS | ★ 8.14 | N/A |
| Revenue | ★ $751,583,000.00 | N/A |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $5.14 | N/A |
| P/E Ratio | $21.57 | ★ N/A |
| Revenue Growth | ★ 9.33 | N/A |
| 52 Week Low | $132.17 | $5.29 |
| 52 Week High | $227.29 | $26.95 |
| Indicator | CRAI | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 53.73 | 51.49 |
| Support Level | $170.00 | $14.24 |
| Resistance Level | $179.62 | $16.66 |
| Average True Range (ATR) | 6.18 | 0.70 |
| MACD | -0.35 | -0.03 |
| Stochastic Oscillator | 58.47 | 56.16 |
CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.